Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tacedinaline, givinostat, cudc-101 +9 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 827 | 0.74 |
| pathways Reactome | 6 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 10095
Sealed predictions
- HDAC5 in dopamine neurons, braak+0.21 (p 0.586) → -0.52 (p 0.150)receipt 10101
Swarm cases
receipt 10101: HDAC5 in dopamine neurons, braak
- power
- full sample -0.39 (p 0.114, n 18), 95% CI -0.72 to +0.10. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.37 (p 0.127, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.41 (p 0.095, n 18). could be the mix.
- skeptic
- leave-one-out range -0.50 to -0.30, sign flips 0; without severely affected donors -0.39 (p 0.114, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.77 (p 1.8e-4, n 18) vs -0.39 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for HDAC5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up HDAC5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.05 p 0.859 (needs p < 2.1e-4)
Receipts
loading the receipts